-
-
Humanized model of the immune system
-
iHuPBMC-T
-
iHuPBMC-NK
-
iHuPBMC-B
-
PBMC-LT
-
CD34+ HSC
-
Winn model
-
iHuPBMC-MHC/KO
-
iHuPBMC-OncVax
-
PBMC mixed inoculation model
more -
-
In vivo tumor experimental platform
-
CDX
-
iHuPDX
-
Non-GLP Toxicology
-
PK/PD
-
Brain in situ model
-
Other in situ models
-
Hematologic tumor model system inoculation
-
Creation of high interstitial tumor models
more -
-
In vitro killing experiment platform
-
Immune co-culture killing model
-
CDC
-
In vitro killing experiment platform
-
IC50
-
PDC High-Throughput In Vitro Pharmacodynamics
-
3D organoids
-
ADCC
-
T cell-mediated killing experiment
more -
-
Mouse-derived immune system model
more -
Tumor vaccine
more -
Cell therapy
more -
In vitro testing platform
more -
Non-GLP Toxicology Platform
more -
Non-tumor model and drug efficacy evaluation platform
more
-
-
-
PDX model
-
PDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
CDX model
-
CDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
Homogeneous Model
-
Homogeneous Model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Breast cancer
-
Stomach cancer
-
Liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Pancreatic cancer
-
Kidney cancer
-
Bladder cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer
-
Ovarian cancer
-
Esophageal cancer
-
Skin cancer
-
sarcoma
-
Nervous System Cancer
-
Embryonal carcinoma
-
Lymphoma
-
Leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other
-
Colorectal cancer
more -
-
News Center
——
Overview of iHuPBMC-T Technology from InnoModels Biotechnology
Author:
InnoModels
Release time:
2024-11-27
In recent years, many breakthroughs have been made in the field of biomedical research, among which iHuPBMC-T technology is undoubtedly a shining star. As an innovative platform built by InnoModels Biotechnology (Beijing) Co., Ltd, iHuPBMC-T, with its unique technological advantages, shows great potential in optimizing the reconstruction of human peripheral blood single nucleated cell (PBMC) model and immuno-oncology research.
1、Technology background and significance
The birth of iHuPBMC-T technology aims to solve the major challenges of traditional immune system tumor models in which tumor growth and PBMC are antagonistic to each other and the cycle is difficult to match. Through this technology, researchers are able to efficiently reconstruct the human immune system, providing excellent tools and resources to support drug discovery, tumor immunotherapy and other research. The emergence of this technology not only improves the success rate of experiments, but also promotes the in-depth development of biomedical research.
2、Technology features and advantages
iHuPBMC-T technology has significant technical features and advantages. Firstly, the platform adopts advanced cell culture and expansion technology, which can efficiently rebuild the human immune system and ensure the accuracy and reliability of experimental results. Second, the iHuPBMC-T platform is highly stable, capable of maintaining the activity and function of immune cells for a long period of time, providing a stable experimental environment for researchers. In addition, the platform is compatible with most tumor cells, providing an ideal choice for tumor vaccines and other immunotherapy studies that require antigen presentation.
3、 Application Prospects and Outlook
The iHuPBMC-T technology has a wide range of application prospects in the field of biomedical research. In drug research and development, this technology can simulate the real environment of the human immune system and provide powerful support for drug screening and drug efficacy evaluation. In tumor immunotherapy, iHuPBMC-T technology helps researchers to more deeply study the interaction between the immune system and tumors and explore new treatment strategies. In addition, with the development of individualized precision medicine, iHuPBMC-T technology is expected to play a greater role in the future, providing more precise and effective treatment options for tumor patients.
4、Conclusion
In summary, iHuPBMC-T technology, as an innovative achievement in biomedical research, has unique technical advantages and wide application prospects. It not only solves the difficulties in traditional immune system tumor models, but also provides excellent tools and resource support for researchers. In the future, with the continuous development and improvement of the technology, iHuPBMC-T technology is expected to play a greater role in the field of biomedical research and make greater contributions to human health.
Chuangmo Biotechnology (Beijing) Co., Ltd.
-
Telephone:+8615010000264 +8613810723384
-
E-mail:cndw@imodels.tech
-
Address: Building 14, Life Valley, Shuangying West Road, Changping District, Beijing
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.
These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.
These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.
These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.
Chuangmo Biotechnology (Beijing) Co., Ltd